“Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study”, J of Skin, vol. 7, no. 6, p. s254, Nov. 2023, doi: 10.25251/skin.7.supp.254.